Introduction {#jcmm12773-sec-0001}
============

Cancer poses an substantial burden on society worldwide, and the incidence rate of cancer remains rising due to the growth of ageing populations and increasing exposure to well‐established risk factors, such as smoking, overweight, and physical inactivity. According to GLOBOCAN estimates, there were approximately 14.1 million new cases and 8.2 million new cancer‐related deaths that occurred in 2012 worldwide [1](#jcmm12773-bib-0001){ref-type="ref"}. Among them, about 951,600 new stomach cancer cases and 723,100 deaths occurred in 2012. Stomach cancer is the third most common cause of cancer‐related death, just next to lung cancer and liver cancer that led to 1,589,900 and 745,500 death respectively. The highest risk area involves the Eastern Asia (including China), Central and Eastern Europe, and South America, while the Northern America and most parts of Africa are the lowest risk area [1](#jcmm12773-bib-0001){ref-type="ref"}. The risk factors of stomach cancer include the consumption of salted and nitrated foods, cigarette smoking, low intake of fresh fruits and vegetables [2](#jcmm12773-bib-0002){ref-type="ref"}. Overweight and obesity may be a risk factor for residents in Western countries [3](#jcmm12773-bib-0003){ref-type="ref"}, but not for Chinese subjects [4](#jcmm12773-bib-0004){ref-type="ref"}. *Helicobacter pylori* infection is an important and well‐established aetiologic factor for stomach cancer in all populations worldwide, and the infected individuals by *H. pylori* show about 3‐ to 6‐fold increased risk of developing stomach cancer [5](#jcmm12773-bib-0005){ref-type="ref"}. However, even in the regions with a high prevalence of *H. pylori* (*e.g*., South America, Asia, Africa and Eastern Europe), only a small proportion of individuals eventually develop stomach cancer. Taken together, it suggests that environmental factors are necessary, but not sufficient to cause cancer, and genetic susceptibility may play a critical role in the tumorigenesis of stomach cancer [6](#jcmm12773-bib-0006){ref-type="ref"}.

DNA repair genes play important roles in maintaining the stability and integrity of genome. More than 130 genes are involved in the different DNA repair pathways, including nucleotide excision repair (NER) pathway [7](#jcmm12773-bib-0007){ref-type="ref"}. The NER pathway is the primary mechanism for the removal of DNA adducts and lesions caused by chemical adducts, and thus is an important part of the cellular defense against a large variety of structurally unrelated DNA lesions [8](#jcmm12773-bib-0008){ref-type="ref"}, [9](#jcmm12773-bib-0009){ref-type="ref"}. In humans, xeroderma pigmentosum group G (XPG) is one of the seven XP complementation groups (XPA to XPG) that have been identified [10](#jcmm12773-bib-0010){ref-type="ref"}. It functions as an endonuclease that can cut the damaged DNA at the 3′ sites of the lesion during the process of DNA repair [11](#jcmm12773-bib-0011){ref-type="ref"}.

As so far, most of the studies that investigated the association between polymorphisms in the *XPG* gene and cancer susceptibility have focused on rs17655 C\>G polymorphism and results are not conclusive [12](#jcmm12773-bib-0012){ref-type="ref"}. Moreover, studies on stomach cancer were very few. There were only two studies having examined the association of *XPG* rs17655 C\>G with stomach cancer risk [13](#jcmm12773-bib-0013){ref-type="ref"}, [14](#jcmm12773-bib-0014){ref-type="ref"}. In addition, three studies investigating potentially functional single nucleotide polymorphisms (SNPs) and stomach cancer risk were published more recently [15](#jcmm12773-bib-0015){ref-type="ref"}, [16](#jcmm12773-bib-0016){ref-type="ref"}, [17](#jcmm12773-bib-0017){ref-type="ref"}. Therefore, it is imperative to identify new susceptibility loci in the *XPG* gene for stomach cancer. In this study, we selected four potentially functional SNPs (rs2094258 C\>T, rs751402 C\>T, rs2296147 T\>C and rs873601G\>A) and explored their association with stomach cancer susceptibility in a hospital‐based case--control study with 692 stomach cancer cases and 774 healthy controls.

Materials and methods {#jcmm12773-sec-0002}
=====================

Study population {#jcmm12773-sec-0003}
----------------

The current case--control study consisted of 692 stomach cancer cases and 774 healthy controls recruited from the First Affiliated Hospital of Wenzhou Medical University between January 2010 and September 2013. Details of the characteristics of the subjects in this case--control study were described previously [18](#jcmm12773-bib-0018){ref-type="ref"}. All cases were histologically/pathologically confirmed by two experienced pathologists. All the 774 healthy controls were individuals receiving the health screening in the same hospital, and they were frequency‐matched to the cases by gender and age distribution. All of the participants provided written informed consent. This study was approved by the Clinical Research Ethics Committee of Wenzhou Medical University.

DNA extraction and genotyping {#jcmm12773-sec-0004}
-----------------------------

Genomic DNA used for the assay was extracted from peripheral blood samples as described previously [16](#jcmm12773-bib-0016){ref-type="ref"}. We chose the three potentially functional SNPs (rs2094258 C\>T, rs2296147 T\>C and rs873601G\>A) following a previously published protocol [16](#jcmm12773-bib-0016){ref-type="ref"}. We also chose the rs751402 C\>T that is located in the 5′ UTR region which was reported in another study [15](#jcmm12773-bib-0015){ref-type="ref"}. Taqman real time PCR method was performed to detect the genotypes of the four selected potentially functional SNPs by using a 7900 HT sequence detector system (Applied Biosystems, Foster City, CA, USA). PCR reactions were carried out in 384 wells with a total volume of 5 μl containing 10 ng of genomic DNA for each SNP. At least 10% of the samples were randomly selected and re‐genotyped to ensure the accuracy of the analysis.

Statistical analysis {#jcmm12773-sec-0005}
--------------------

Chi‐squared test were performed to examine the differences in the distribution of various characteristics and genotype frequencies between the stomach cancer cases and the healthy controls. Goodness‐of‐fit chi‐squared test was performed to assess the Hardy--Weinberg equilibrium (HWE) for each SNP by comparing observed and expected genotype frequencies. Odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were calculated to evaluate the strength of the association between these four SNPs and stomach cancer risk by logistic regression. We managed all the statistical analysis by using SAS software (version 9.1; SAS Institute, Cary, NC, USA). A two‐sided *P*‐value less than 0.05 was considered to be statistically significant.

Results {#jcmm12773-sec-0006}
=======

Population characteristics {#jcmm12773-sec-0007}
--------------------------

All the stomach cancer cases and healthy controls were from Chinese Han descent. The characteristics of the study population are shown in Table S1. Three samples in controls failed in spite of repeated genotyping tests, thus a total of 692 stomach cancer patients and 771 healthy controls were included in the final analysis. The mean age (±SD) for case and control groups was 59.22 (±11.05) and 59.71 (±11.35) years respectively. Cases consisted of 492 men and 200 women, while healthy controls included 546 men and 225 women. No significant difference was observed in the age and gender distribution between two groups (*P* = 0.864 and *P* = 0.906 respectively). Compared to the healthy controls, the stomach cases were more likely to be non‐smokers (*P* \< 0.0001), non‐drinkers (*P* = 0.0005) as well as nutrient deficient and with lower BMI (*P* \< 0.0001).

Distributions of selected SNPs and risk of stomach cancer {#jcmm12773-sec-0008}
---------------------------------------------------------

The genotypes and allele frequencies of the four polymorphisms were shown in Table [1](#jcmm12773-tbl-0001){ref-type="table-wrap"}. The observed genotype frequency distributions of the four polymorphisms were in consistent with HWE for controls (*P* = 0.803 for rs2094258 C\>T, *P* = 0.416 for rs751402 C\>T, *P* = 0.535 for rs2296147 T\>C and *P* = 0.415 for rs873601G\>A). The significant differences in genotype frequency distribution were only observed for the rs873601G\>A polymorphism between cases and controls. Compared with carriers of the rs873601GG/AG genotypes, carriers of the AA genotype had a significantly increased stomach cancer risk (OR = 1.31, 95% CI = 1.03--1.66, *P* = 0.027). We also found that the presence of two risk genotypes significantly conferred increased stomach cancer risk (OR = 1.52, 95% CI = 1.13--2.06, *P* = 0.006, and adjusted OR = 1.44, 95% CI = 1.03--2.01, *P* = 0.035). Moreover, the risk of developing stomach cancer was also significantly increased among those carrying one or more risk genotypes (OR = 1.32, 95% CI = 1.04--1.69, *P* = 0.025).

###### 

Logistic regression analysis of associations between the genotypes of *XPG* and stomach cancer susceptibility in a Chinese population

  Genotype                            Cases (*N* = 692)   Controls (*N* = 771)   *P* [a](#jcmm12773-note-0001){ref-type="fn"}    Crude OR (95% CI)       *P*         Adjusted OR (95% CI)[b](#jcmm12773-note-0002){ref-type="fn"}   *P* [b](#jcmm12773-note-0002){ref-type="fn"}
  ----------------------------------- ------------------- ---------------------- ----------------------------------------------- ----------------------- ----------- -------------------------------------------------------------- ----------------------------------------------
  rs2094258 C\>T                                                                                                                                                                                                                    
  CC                                  287 (41.47)         291 (37.74)            0.296[c](#jcmm12773-note-0003){ref-type="fn"}   1.00                                1.00                                                           
  CT                                  304 (43.93)         368 (47.73)                                                            0.84 (0.67--1.05)       0.119       0.85 (0.68--1.06)                                              0.150
  TT                                  101 (14.60)         112 (14.53)                                                            0.91 (0.67--1.25)       0.577       0.92 (0.67--1.26)                                              0.601
  Additive                                                                                                                       0.93 (0.80--1.08)       0.313       0.93 (0.80--1.08)                                              0.347
  Dominant                            405 (58.53)         480 (62.26)            0.145[d](#jcmm12773-note-0004){ref-type="fn"}   0.86 (0.69--1.06)       0.145       0.86 (0.70--1.07)                                              0.177
  Recessive                           591 (85.40)         659 (85.47)            0.970[e](#jcmm12773-note-0005){ref-type="fn"}   1.01 (0.75--1.35)       0.970       1.00 (0.75--1.35)                                              0.980
  rs751402 C\>T                                                                                                                                                                                                                     
  CC                                  286 (41.33)         351 (45.53)            0.227[c](#jcmm12773-note-0003){ref-type="fn"}   1.00                                1.00                                                           
  CT                                  313 (45.23)         331 (42.93)                                                            1.16 (0.93--1.45)       0.184       1.17 (0.91--1.49)                                              0.221
  TT                                  93 (13.44)          89 (11.54)                                                             1.28 (0.92--1.78)       0.140       1.11 (0.77--1.61)                                              0.576
  Additive                                                                                                                       1.14 (0.98--1.33)       0.088       1.09 (0.92--1.29)                                              0.335
  Dominant                            406 (58.67)         420 (54.47)            0.106[d](#jcmm12773-note-0004){ref-type="fn"}   1.19 (0.96--1.46)       0.106       1.15 (0.92--1.45)                                              0.226
  Recessive                           599 (86.56)         682 (88.46)            0.273[e](#jcmm12773-note-0005){ref-type="fn"}   1.19 (0.87--1.62)       0.272       1.03 (0.73--1.46)                                              0.872
  rs2296147 T\>C                                                                                                                                                                                                                    
  TT                                  442 (63.87)         475 (61.61)            0.464[c](#jcmm12773-note-0003){ref-type="fn"}   1.00                                1.00                                                           
  CT                                  217 (31.36)         264 (34.24)                                                            0.88 (0.71--1.10)       0.273       0.93 (0.73--1.19)                                              0.562
  CC                                  33 (4.77)           32 (4.15)                                                              1.11 (0.67--1.83)       0.688       1.38 (0.78--2.44)                                              0.268
  Additive                                                                                                                       0.95 (0.80--1.14)       0.586       1.03 (0.84--1.25)                                              0.809
  Dominant                            250 (36.13)         296 (38.39)            0.371[d](#jcmm12773-note-0004){ref-type="fn"}   0.91 (0.73--1.12)       0.372       0.97 (0.77--1.23)                                              0.823
  Recessive                           659 (95.23)         739 (95.85)            0.567[e](#jcmm12773-note-0005){ref-type="fn"}   1.16 (0.70--1.90)       0.566       1.41 (0.81--2.48)                                              0.227
  rs873601G\>A                                                                                                                                                                                                                      
  GG                                  172 (24.86)         205 (26.59)            0.087[c](#jcmm12773-note-0003){ref-type="fn"}   1.00                                1.00                                                           
  GA                                  333 (48.12)         396 (51.36)                                                            1.00 (0.78--1.29)       0.986       1.08 (0.81--1.42)                                              0.604
  AA                                  187 (27.02)         170 (22.05)                                                            1.31 (0.98--1.75)       0.067       1.33 (0.96--1.84)                                              0.086
  Additive                                                                                                                       1.14 (0.99--1.32)       0.071       1.15 (0.98--1.36)                                              0.088
  Dominant                            520 (75.14)         566 (73.41)            0.449[d](#jcmm12773-note-0004){ref-type="fn"}   1.10 (0.87--1.39)       0.450       1.15 (0.89--1.50)                                              0.287
  Recessive                           505 (72.98)         601 (77.95)            0.027[e](#jcmm12773-note-0005){ref-type="fn"}   **1.31 (1.03--1.66)**   **0.027**   1.27 (0.97--1.65)                                              0.084
  Combined effect of risk genotypes                                                                                                                                                                                                 
  0                                   145 (20.95)         200 (25.94)            0.023[c](#jcmm12773-note-0003){ref-type="fn"}   1.00                                1.00                                                           
  1                                   367 (53.03)         408 (52.92)                                                            1.24 (0.96--1.60)       0.099       1.20 (0.90--1.60)                                              0.211
  2                                   180 (26.01)         163 (21.14)                                                            **1.52 (1.13--2.06)**   **0.006**   **1.44 (1.03--2.01)**                                          **0.035**
  0                                   145 (20.95)         200 (25.94)                                                            1.00                                1.00                                                           
  1--2                                547 (79.05)         571 (74.06)            0.025                                           **1.32 (1.04--1.69)**   **0.025**   1.27 (0.97--1.66)                                              0.088

Chi‐squared test for genotype distributions between stomach cancer cases and controls.

Adjusted for age, gender, BMI, smoking and drinking status.

Additive models.

Dominant models.

Recessive models.

OR, odds ratio; CI, confidence interval.

The results were in bold, if the 95% CI excluded 1 or P\<0.05.

John Wiley & Sons, Ltd

Stratification analysis {#jcmm12773-sec-0009}
-----------------------

We further explored the association between *XPG* polymorphisms and stomach cancer risk in stratification analysis by age, gender, smoking status, pack‐year, drinking status, BMI and tumour sites (Table [2](#jcmm12773-tbl-0002){ref-type="table-wrap"}). First of all, we only found that the rs873601 AA genotype was shown to significantly increase stomach cancer risk among the older subjects (adjusted OR = 1.54, 95% CI = 1.05--2.25, *P* = 0.028) and the non‐cardia subjects (adjusted OR = 1.36, 95% CI = 1.01--1.82, *P* = 0.041). We also observed a borderline significantly increased stomach cancer risk for the men (adjusted OR = 1.37, 95% CI = 1.00--1.89, *P* = 0.052) and ever smokers (adjusted OR = 1.43, 95% CI = 0.95--2.15, *P* = 0.085). We next combined the four SNPs, and found that the presence of one or two risk genotypes was significantly associated with increased stomach cancer risk among men (adjusted OR = 1.40, 95% CI = 1.01--1.93, *P* = 0.043), ever smokers (adjusted OR = 1.83, 95% CI = 1.20--2.80, *P* = 0.005), subjects with pack‐years ≤27 (adjusted OR = 1.83, 95% CI = 1.02--3.23, *P* = 0.045) and never drinkers (adjusted OR = 1.41, 95% CI = 1.02--1.94, *P* = 0.036).

###### 

Stratification analysis of *XPG* rs873601G\>A and risk genotypes with stomach cancer susceptibility

  Variables          rs873601 (cases/controls)   Adjusted OR[a](#jcmm12773-note-0007){ref-type="fn"} (95% CI)   *P* [a](#jcmm12773-note-0007){ref-type="fn"}   Risk genotypes (cases/controls)   Adjusted OR[a](#jcmm12773-note-0007){ref-type="fn"} (95% CI)   *P* [a](#jcmm12773-note-0007){ref-type="fn"}                           
  ------------------ --------------------------- -------------------------------------------------------------- ---------------------------------------------- --------------------------------- -------------------------------------------------------------- ---------------------------------------------- ----------------------- -----------
  Median age, year                                                                                                                                                                                                                                                                                                                     
  ≤59                249/275                     84/85                                                          1.05 (0.72--1.53)                              0.812                             64/92                                                          269/268                                        1.44 (0.97--2.14)       0.070
  \>59               256/326                     103/85                                                         **1.54 (1.05--2.25)**                          **0.028**                         81/108                                                         278/303                                        1.13 (0.77--1.65)       0.538
  Gender                                                                                                                                                                                                                                                                                                                               
  Females            146/170                     54/55                                                          1.06 (0.65--1.75)                              0.810                             45/55                                                          155/170                                        1.04 (0.62--1.74)       0.891
  Males              359/431                     133/115                                                        1.37 (1.00--1.89)                              0.052                             100/145                                                        392/401                                        **1.40 (1.01--1.93)**   **0.043**
  Smoking status                                                                                                                                                                                                                                                                                                                       
  Never              310/275                     117/86                                                         1.14 (0.80--1.64)                              0.463                             98/82                                                          329/279                                        0.94 (0.65--1.36)       0.737
  Ever               195/326                     70/84                                                          1.43 (0.95--2.15)                              0.085                             47/118                                                         218/292                                        **1.83 (1.20--2.80)**   **0.005**
  Pack‐year                                                                                                                                                                                                                                                                                                                            
  0                  310/275                     117/86                                                         1.14 (0.80--1.64)                              0.463                             98/82                                                          329/279                                        0.94 (0.65--1.36)       0.737
  ≤27                100/201                     33/49                                                          1.29 (0.73--2.29)                              0.385                             24/75                                                          109/175                                        **1.83 (1.02--3.33)**   **0.045**
  \>27               95/125                      37/35                                                          1.52 (0.82--2.84)                              0.185                             23/43                                                          109/117                                        1.87 (0.97--3.61)       0.062
  Drinking status                                                                                                                                                                                                                                                                                                                      
  Never              394/420                     145/119                                                        1.26 (0.92--1.73)                              0.144                             108/140                                                        431/399                                        **1.41 (1.02--1.94)**   **0.036**
  Ever               111/181                     42/51                                                          1.27 (0.75--2.13)                              0.377                             37/60                                                          116/172                                        0.97 (0.57--1.64)       0.896
  BMI                                                                                                                                                                                                                                                                                                                                  
  \<18.5             38/4                        15/1                                                           1.76 (0.17--18.58)                             0.640                             13/1                                                           40/4                                           0.87 (0.08--9.37)       0.907
  18.5--24.0         301/195                     122/49                                                         1.62 (1.11--2.38)                              0.013                             87/61                                                          336/183                                        1.30 (0.89--1.90)       0.170
  \>24.0             166/402                     50/120                                                         1.00 (0.68--1.47)                              0.993                             45/138                                                         171/384                                        1.33 (0.90--1.97)       0.148
  Tumour sites                                                                                                                                                                                                                                                                                                                         
  Cardia             148/601                     51/170                                                         1.17 (0.79--1.74)                              0.433                             43/200                                                         156/571                                        1.16 (0.78--1.73)       0.472
  Non‐cardia         357/601                     136/170                                                        **1.36 (1.01--1.82)**                          **0.041**                         102/200                                                        391/571                                        1.33 (0.98--1.81)       0.064

Adjusted for age, gender, BMI, smoking and drinking status.

OR: odds ratio; CI: confidence interval; BMI: body mass index.

The results were in bold, if the 95% CI excluded 1 or P\<0.05.

John Wiley & Sons, Ltd

Discussion {#jcmm12773-sec-0010}
==========

In the current hospital‐based case--control study, we assessed the association between four potentially functional SNPs in the *XPG* gene and the risk of stomach cancer in Chinese Han population. We found a significant association between *XPG* rs873601 G\>A polymorphism and stomach cancer susceptibility, especially in older subjects and subjects with non‐cardia stomach cancer. We also observed the individuals carrying one or two risk genotypes had a significantly increased stomach cancer risk, especially among ever smokers and men.

*XPG* gene, also known as *ERCC5*, is located at 13q33 and consists of 15 exons. There are at least 2430 reported SNPs in the gene region (<http://www.ncbi.nlm.nih.gov/SNP>). XPG is a structure‐specific endonuclease. It participates in both the transcription‐coupled repair [19](#jcmm12773-bib-0019){ref-type="ref"} and the global genomic NER [20](#jcmm12773-bib-0020){ref-type="ref"} steps, which are critical for correcting the excision repair deficiency. As reported, XPG may also play important roles in other cellular processes, such as RNA polymerase II transcription and transcription‐coupled DNA repair [21](#jcmm12773-bib-0021){ref-type="ref"}. Xeroderma pigmentosum group G can excise damaged oligonucleotide by cleaving the 3′ damaged site during NER. The XPF/ERCC1 complex may participate in the 5′ incision, and stabilize the binding of DNA repair complex to damaged DNA [22](#jcmm12773-bib-0022){ref-type="ref"}, [23](#jcmm12773-bib-0023){ref-type="ref"}, [24](#jcmm12773-bib-0024){ref-type="ref"}.

Polymorphism in the *XPG* gene may be associated with cancer susceptibility. In a recent study including a total of 878 colorectal cancer (CRC) patients and 884 controls, Du *et al*. [25](#jcmm12773-bib-0025){ref-type="ref"} found a significant increased CRC risk for the carriers of *XPG* rs17655 CG/GG genotypes (OR = 1.39, 95% CI = 1.14--1.69). In the same study, a meta‐analysis was also performed on the association of the SNP with CRC risk, with a total of 2649 CRC cases and 2848 controls included. The association between *XPG* rs17655 and CRC risk was replicated under the dominant model (CG/GG *versus* CC: OR = 1.35, 95% CI = 1.20--1.51) in the pooled analysis. Thus far, several studies have been carried out to investigate the association between *XPG* polymorphisms and stomach cancer susceptibility. Hussain *et al*.[13](#jcmm12773-bib-0013){ref-type="ref"} performed a population‐based study with 196 stomach cancer cases and 397 controls. They found that the rs2227869G\>C polymorphism was associated with decreased stomach cancer susceptibility, while no association was found for the rs1047768 T\>C and rs17655 C\>G. Canbay *et al*. [14](#jcmm12773-bib-0014){ref-type="ref"} conducted a study involving only 40 stomach cancer cases and 247 controls, and failed to find any association between rs17655 C\>G polymorphism and stomach cancer susceptibility. He *et al*. [16](#jcmm12773-bib-0016){ref-type="ref"} genotyped three potentially functional *XPG* SNPs (rs2094258 C\>T, rs2296147 T\>C and rs873601G\>A) in 1125 stomach cancer cases and 1196 controls. They found carriers of the rs873601 A had a significantly increased stomach cancer risk. Consistently, they also demonstrated that the A allele were significantly associated with reduced mRNA expression level of *XPG* gene. Duan *et al*. [15](#jcmm12773-bib-0015){ref-type="ref"} focused on SNPs in the promoter region of *XPG* gene and genotyped the rs751402 C\>T and rs2296147 T\>C polymorphisms in a total of 403 stomach cancer cases and 403 controls. Both of the two polymorphisms were shown to significantly increase stomach cancer risk. In another study with 337 stomach cancer cases and 347 controls, Yang *et al*. [17](#jcmm12773-bib-0017){ref-type="ref"} found that the rs2296147 T\>C polymorphism was associated with decreased stomach cancer risk, while the rs2094258 C\>T polymorphism was associated with increased stomach cancer risk. However, no significant association was found for the rs873601G\>A polymorphism. In this study with 692 stomach cancer cases and 771 controls, we found that only the *XPG* rs873601G\>A polymorphism is associated with slightly increased stomach cancer risk. No association with stomach cancer risk was found for the remaining SNPs, which may be partially ascribed to the weak effect of each SNP. Besides, the sample size in this study was moderate and might not be large enough to detect relatively weak association. Moreover, the positive findings by others with smaller sample size may be due to a chance.

Despite the significant findings, several limitations should be addressed. First, the sample size is moderate, with only 692 cases and 771 controls included. The relative small sample size might not be able to reveal some weak gene‐disease association and gene‐environment interactions. Second, some valuable information on other exposures for individual participants was missing, such as *H. pylori* infection, occupation and local environmental factors, diet, physical activity. Third, only four potentially functional SNPs were included in this study, and SNPs from the coding and the intron regions that may also be related to stomach cancer risk were omitted. Finally, functional analysis was not performed for the studied SNPs.

In conclusion, this study provided evidence of the associations between four potentially functional SNPs in the *XPG* gene and the risk of stomach cancer. In particular, we found that the *XPG* rs873601G\>A polymorphism was associated with slightly increased stomach cancer risk in Chinese Han population. In the future, prospective studies with different ethnicities and larger sample size as well as investigations into mechanism are warranted to validate the role of *XPG* SNPs in stomach cancer carcinogenesis and explore the underlying mechanism.
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**Table S1** Frequency distribution of selected characteristics in stomach cancer cases and controls.
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Click here for additional data file.
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